Editing Muscle-Invasive Bladder Cancer (section)

====== Histological considerations ======
* '''<span style="color:#ff0000">NAC is primarily derived in the urothelial carcinoma setting</span>'''
** '''Secondary analysis of SWOG 8710 found that patients with mixed tumours (squamous and glandular differentiation) derived greater benefit''' (HR 0.46) '''from neoadjuvant MVAC than patients with pure urothelial carcinoma''' (HR 0.9), compared with cystectomy[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117124/ §]
* '''<span style="color:#ff0000">Lack of robust data supporting NAC in pure non-urothelial histologies</span>'''
** '''Exceptions are pure small cell or pure neuroendocrine carcinoma of the bladder where NAC is the mainstay of treatment'''
** '''[CUA Guidelines do not support NAC in pure non-urothelial histology, other than noted exceptions]'''